FDA Warning Letters to GLP-1 Compounders: What Patients Need to Know
The FDA has issued more than 80 warning letters to GLP-1 compounders and telehealth companies since September 2025. Here's what they actually say, why they matter, and how to verify your provider isn't on the list.
Between September 2025 and March 2026, the FDA launched its most aggressive enforcement campaign against the compounded GLP-1 industry. The agency sent warning letters in two major waves — and the content of those letters tells a clear story about what the FDA is targeting and why.
Wave 1: September 2025
On September 16, 2025, the FDA issued more than 55 warning letters to companies that compound or manufacture GLP-1 semaglutide and tirzepatide. The letters were not about compounding itself being illegal — they were about marketing claims.
Specifically, the FDA cited companies for claiming their compounded products were "generic" versions of FDA-approved drugs, that they contained the "same active ingredient" with equivalent safety and efficacy, and that they offered "real results" or "proven effectiveness." The agency's position: compounded drugs have not been reviewed by the FDA for safety, effectiveness, or quality, and making such claims is false and misleading.
The September wave was broadly aimed — hitting both small compounders and large operations. It also included warnings to brand-name manufacturers, with the FDA flagging a prime-time TV special that it said created misleading impressions about safety.
Wave 2: March 2026
On March 3, 2026, the FDA issued 30 additional warning letters, this time focused squarely on telehealth companies. The agency had reviewed these companies' websites in December 2025, documenting instances where they claimed their compounded products contained the same ingredients as branded medications or had been tested in clinical trials.
The March wave was more targeted. It focused primarily on small to midsize telehealth companies and online wellness clinics — leaving larger platforms largely untouched. Each letter threatened "legal action without further notice" if companies didn't respond with corrective action within 15 working days.
What the Letters Actually Target
Reading the warning letters reveals a consistent set of claims the FDA considers problematic:
| Claim Type | FDA's Position |
|---|---|
| "Same active ingredient as Ozempic/Wegovy" | Misleading — compounded products have not been evaluated by FDA for safety, efficacy, or quality |
| "Generic semaglutide/tirzepatide" | False — no generic versions of these drugs are FDA-approved; compounded products are not generics |
| "Clinically proven" or "proven effectiveness" | Misleading — clinical trial data applies to FDA-approved products, not compounded versions |
| "FDA-approved ingredients" | Misleading — the bulk ingredient may be pharmaceutical grade, but the compounded product itself is not FDA-approved |
| "Same results as brand-name" | Unsubstantiated — no clinical trial has evaluated compounded formulations head-to-head against branded products |
The Hims & Hers Resolution
Days after the March 2026 warning letters, Novo Nordisk and Hims & Hers Health announced a partnership resolution. Under the agreement, Hims & Hers would begin offering Novo Nordisk's branded semaglutide products (Ozempic and Wegovy) on its telehealth platform, while scaling back advertising and marketing of compounded GLP-1 alternatives. In return, Novo Nordisk dismissed its patent infringement lawsuit. FDA Commissioner Makary publicly endorsed the deal.
This arrangement may serve as a template for how other large telehealth platforms navigate the evolving regulatory environment — pivoting from compounded to branded products while maintaining patient access through their existing platforms.
Safety Concerns Behind the Enforcement
The FDA's enforcement is not purely regulatory posturing. By early 2025, the agency had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 associated with compounded tirzepatide. Many of these involved dosing errors from patients self-administering incorrect amounts from multidose vials — some requiring hospitalization.
Concerns about counterfeit products entering the market through online channels have further reinforced the FDA's enforcement focus. In February 2025, the National Association of Attorneys General sent a letter to the acting FDA commissioner asking the agency to stop "bad actors" from profiting off counterfeit incretin-based drugs.
If your GLP-1 provider's website claims their compounded medication is "the same as Ozempic," is "FDA-approved," references clinical trial results as applying to their product, or doesn't mention that compounded medications have not been evaluated by the FDA — those are exactly the claims the FDA has been targeting. Consider verifying your provider's compliance and pharmacy licensing.
What This Means for Patients
The warning letters don't make compounding illegal — they address how providers market their products. Patient-specific compounding through licensed 503A pharmacies with valid prescriptions remains legal. The distinction matters: you can still access compounded GLP-1 medications through compliant providers.
The key is choosing providers that don't make misleading claims, use licensed and inspected compounding pharmacies, and provide genuine medical oversight. Here are verified providers currently accepting new patients:
GLP-1 weight management programs with licensed medical providers and transparent practices.
Programs available
⚠️ Compounded medications are not FDA-approved. Paid link.
GLP-1 treatment with licensed clinical oversight, home delivery, and ongoing support.
Pricing disclosed after consultation
⚠️ Compounded medications are not FDA-approved. Paid link.
Affordable direct care platform — FDA-approved brand-name GLP-1 consultations with licensed clinicians.
Consultations from $99
Paid link.
The FDA's warning letters are about marketing, not about criminalizing patients or all compounding. But they signal an increasingly aggressive regulatory posture. If you're using a compounded GLP-1 medication, verify that your provider uses a licensed 503A compounding pharmacy, provides legitimate medical oversight, and doesn't make claims that the FDA has identified as misleading.
Sources
- Wilson Sonsini. FDA Sends Warning Letters to More Than 50 GLP-1 Compounders and Manufacturers. October 2025. wsgr.com
- Fierce Pharma. FDA ramps up crackdown on GLP-1 drug compounding with fresh batch of 30 warning letters. March 2026. fiercepharma.com
- Pharmacy Times. FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Takedown. May 2026. pharmacytimes.com
- Frier Levitt. From Crackdown to Collaboration: FDA Warning Letters and the Hims-Novo Nordisk Deal. March 2026. frierlevitt.com
- Pharmacy Times. FDA Moves to Permanently Close the Door on Compounded GLP-1s. May 2026. pharmacytimes.com
Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content or sourcing standards.